Primary refractory multiple myeloma : a real-world experience with 85 cases
| Autor: | Julio Davila Valls, Parameswaran Hari, Martin Stork, Saurabh Chhabra, Iwona Hus, Massimo Gentile, Gergely Varga, Jan Walewski, Agnieszka Druzd-Sitek, Anna Waszczuk-Gajda, Katarzyna Krawczyk, Marek Rodzaj, Jorge J. Castillo, Lidia Usnarska-Zubkiewicz, Natalia Schutz, David H. Vesole, Ludek Pour, Ajay K. Nooka, Gabor Mikala, Stanisław Potoczek, Ravi Vij, Agnieszka Porowska, Artur Jurczyszyn, Chor Sang Chim, Mark A. Fiala |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Treatment response Transplantation Autologous Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Overall response rate Induction therapy Internal medicine medicine Humans Multiple myeloma Retrospective Studies business.industry Hematopoietic Stem Cell Transplantation Refractory Multiple Myeloma Hematology medicine.disease Prognosis Progression-Free Survival Treatment Outcome 030220 oncology & carcinogenesis business Multiple Myeloma 030215 immunology |
| Popis: | This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|